MediGene AG

Medigene AG Announces Over Half Equity Loss and Adjusts Cash Flow Timeline

MDG1

Medigene AG has announced the departure of CEO Dr. Selwyn Ho, effective July 24, 2025, with Ralph Schäfer set to take over on July 25, 2025. This leadership change comes amid ongoing preliminary insolvency proceedings, though it is stated to be unrelated. The company has also seen other key personnel departures, including its Chief Scientific Officer. The latest analyst rating for Medigene stock (DE:MDG1) is a Buy, with a price target of EUR2.00.

Tip Ranks

Medigene AG Announces CEO Departure and Leadership Changes Amid Insolvency Proceedings

MediGene AG, an oncology company, has been downgraded from the Prime Standard to the General Standard segment on the Frankfurt Stock Exchange following preliminary insolvency proceedings initiated on April 24, 2024. This downgrade allows the company's shares to continue trading under the same stock identification while it aims to stabilize operations and focus on cancer research and development.

Reuters

Medigene AG Shares Downgraded to General Standard on Frankfurt Stock Exchange Following Insolvency Proceedings

Medigene AG has announced the pre-release of its 2024 financial report, covering January 1 to December 31, 2024, set to be published online on July 31, 2025. This announcement aligns with financial reporting regulations and informs stakeholders of the timeline for detailed financial insights, which may influence investor decisions. Medigene, based in Germany, specializes in developing innovative immunotherapies for cancer treatment. Current market cap stands at €2.97M, with a year-to-date price performance of -79.50%.

Medigene AG Pre-Announces 2024 Financial Report Release

Medigene AG has announced the pre-announcement of its financial report for the year 2024, covering the period from January 1, 2024, to December 31, 2024. The report will be published on July 31, 2025. Medigene is listed on the regulated market in Frankfurt and the free market in several German cities.

pressetext

Pre-announcement of a financial report according to articles 114 - 117 WpHG

Medigene AG has announced its intention to file for insolvency proceedings due to overindebtedness and expected illiquidity by May 2025. This decision, supported by the Executive Management Board and Supervisory Board, follows a reassessment of the company's asset valuation in light of its current economic situation. The filing will be made with the competent local court soon.

Medigene AG Files Application for the Opening of Insolvency Proceedings

Medigene AG has announced a loss of more than half of its share capital, necessitating an Extraordinary General Meeting to report this loss as per German law. Additionally, the company has adjusted its cash runway from July 2025 to May 2025 due to unreceived milestone payments. Medigene's management is actively seeking additional financing while maintaining its 2024 financial guidance for R&D expenses and revenues.

PTA-Adhoc: Medigene AG: Notification of Loss of Half of the Share Capital According to § 92 AktG and Cash Runway Amendment

Medigene AG has filed a patent application for a novel NK cell-specific T cell receptor construct with the European Patent Office. This initiative reflects the company's commitment to enhancing its TCR-guided cancer treatment strategy by incorporating its 3S TCR technology into NK cells. The patent application not only broadens Medigene's intellectual property portfolio but also reinforces its focus on developing innovative immunotherapies for cancer.

Unusual Whales

Medigene files patent for unique NK-specific TCR construct with European Patent Office, expanding its TCR-guided strategy.

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Medigene and EpimAb to develop T cell engagers for solid tumours

On February 27, 2025, it was announced that Medigene AG (MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. have formed a strategic co-development agreement. The focus will be on researching and developing off-the-shelf TCR-guided T Cell Engagers for immune-related disorders like solid tumors. This collaboration aims to advance treatments in this area through innovative therapies. This partnership signifies a significant step forward in the medical research field, potentially leading to groundbreaking advances in addressing immune-related conditions like solid tumors.

Medigene and EpimAb Biotherapeutics team up to develop TCR-TCEs for treating immune-related disorders like solid tumors.

Medigene AG and EpimAb Biotherapeutics have entered a strategic co-development partnership to create TCR-guided T Cell Engagers (TCR-TCEs) for treating immune-related disorders, including solid tumors. This collaboration combines Medigene's TCR generation capabilities with EpimAb's T-FIT platform, aiming to develop bispecific therapeutics that enhance targeted immune responses while minimizing off-target effects. The bispecific therapy market is projected to grow significantly, with an estimated value exceeding USD 80 billion by 2030, highlighting the urgent need for innovative cancer treatments.

PTA-News: Medigene AG: Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers

Medigene AG has updated its total voting rights to 14,887,594, effective February 18, 2025. This change, under Article 41 of the WpHG, may affect the distribution of voting power among shareholders. Medigene, a biotechnology firm based in Germany, focuses on innovative therapeutic solutions and operates in regulated and free markets. The company has a market cap of €13.74M and a year-to-date price performance of 54%.

Medigene AG Updates Total Voting Rights to 14.9 Million

Planegg/Martinsried, February 19, 2025. Medigene AG ( Medigene, FSE: MDG1, Prime Standard ) , an oncology platform company focused on the research and development of T cell receptor ( TCR ) -guided therapies for the treatment of cancer, announced today that the Company has been issued a patent by ...

GlobeNewswire

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.

Planegg/Martinsried, February 3, 2025. Medigene AG ( Medigene or the "Company", FSE: MDG1, Prime Standard ) , an oncology platform company focused on the research and development of T cell receptor ( TCR ) -guided therapies for the treatment of cancer, announced the closing of its first tranche ...